Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Prenylflavonoids from Hops Inhibit the Metabolic Activation of the Carcinogenic Heterocyclic Amine 2-Amino-3-methylimidazo[4,5-f]quinoline, Mediated by cDNA-Expressed Human CYP1A2

Cristobal L. Miranda, Yea-Huey Yang, Marilyn C. Henderson, Jan F. Stevens, Gilberto Santana-Rios, Max L. Deinzer and Donald R. Buhler
Drug Metabolism and Disposition November 2000, 28 (11) 1297-1302;
Cristobal L. Miranda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yea-Huey Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marilyn C. Henderson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan F. Stevens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilberto Santana-Rios
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Max L. Deinzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald R. Buhler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) is a potential human carcinogen found in cooked food that requires initial metabolic activation by cytochrome P450s, primarily CYP1A2. The present study was conducted to examine whether recombinant human CYP1A2 expressed in insect cells mediates the metabolic activation of IQ and whether prenylflavonoids found in hops and beer would modulate the CYP1A2-mediated activation of IQ. The cDNA-expressed human CYP1A2 was found to strongly activate IQ as measured by the Ames Salmonella assay and by the covalent binding of IQ metabolites to calf thymus DNA and protein. Inhibition studies showed that the prenylchalcone xanthohumol and the prenylflavanones 8-prenylnaringenin and isoxanthohumol strongly inhibited the mutagenic activation of IQ mediated by cDNA-expressed human CYP1A2 in the Ames Salmonella assay. The three prenylflavonoids also markedly inhibited the human CYP1A2-mediated binding of IQ to metabolites that bind to DNA. The inhibition of the metabolic activation of IQ was paralleled by the inhibition of acetanilide 4-hydroxylase activity of human CYP1A2. Thus, xanthohumol, isoxanthohumol, and prenylflavanones 8-prenylnaringenin are potent inhibitors of the metabolic activation of IQ and may have the potential to act as chemopreventive agents against cancer induced by heterocyclic amines activated by CYP1A2.

Footnotes

  • Send reprint requests to: Dr. Donald R. Buhler, Ph.D., Professor, Department of Environmental and Molecular Toxicology, Oregon State University, ALS 1007, Corvallis, OR 97331-7301. E-mail:donald.buhler{at}orst.edu

  • Abbreviations used are::
    IQ
    2-amino-3-methylimidazo[4,5-f]quinoline
    PhIP
    2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
    XN
    xanthohumol
    IX
    isoxanthohumol
    8PN
    8-prenylnaringenin
    • Received June 22, 2000.
    • Accepted August 14, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (11)
Drug Metabolism and Disposition
Vol. 28, Issue 11
1 Nov 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prenylflavonoids from Hops Inhibit the Metabolic Activation of the Carcinogenic Heterocyclic Amine 2-Amino-3-methylimidazo[4,5-f]quinoline, Mediated by cDNA-Expressed Human CYP1A2
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Prenylflavonoids from Hops Inhibit the Metabolic Activation of the Carcinogenic Heterocyclic Amine 2-Amino-3-methylimidazo[4,5-f]quinoline, Mediated by cDNA-Expressed Human CYP1A2

Cristobal L. Miranda, Yea-Huey Yang, Marilyn C. Henderson, Jan F. Stevens, Gilberto Santana-Rios, Max L. Deinzer and Donald R. Buhler
Drug Metabolism and Disposition November 1, 2000, 28 (11) 1297-1302;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Prenylflavonoids from Hops Inhibit the Metabolic Activation of the Carcinogenic Heterocyclic Amine 2-Amino-3-methylimidazo[4,5-f]quinoline, Mediated by cDNA-Expressed Human CYP1A2

Cristobal L. Miranda, Yea-Huey Yang, Marilyn C. Henderson, Jan F. Stevens, Gilberto Santana-Rios, Max L. Deinzer and Donald R. Buhler
Drug Metabolism and Disposition November 1, 2000, 28 (11) 1297-1302;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Humanized PXR-CAR-CYP3A4/7 Mouse as Model of Induction
  • Ozanimod Human Metabolism and Disposition
  • High-Throughput Characterization of SLCO1B1 VUS
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics